REVBREVELATION BIOSCIENCES, INC.

Nasdaq revbiosciences.com


$ 0.90 $ -0.03 (-3.84 %)    

Thursday, 15-Aug-2024 12:33:37 EDT
QQQ $ 475.24 $ 0.61 (0.13 %)
DIA $ 406.80 $ 0.86 (0.21 %)
SPY $ 554.24 $ 1.24 (0.22 %)
TLT $ 97.41 $ 0.34 (0.35 %)
GLD $ 231.90 $ 5.08 (2.24 %)
$ 0.861
$ 0.92 x 250
$ 0.89 x 1,636
-- - --
$ 0.81 - $ 28.20
85,371
na
1.41M
$ 1.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-22-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-22-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-14-2022 03-31-2022 10-Q
11 04-15-2022 12-31-2021 10-K
12 10-29-2021 09-30-2021 10-Q
13 08-23-2021 06-30-2021 10-Q
14 06-22-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 revelation-biosciences-q2-2024-gaap-eps-513

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(5.13) per share.

 watching-revelation-biosciences-zacks-small-cap-research-gives-stock-1240-price-valuation

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_07082024_REVB_Sorensen.pdf

 why-is-nano-cap-revelation-biosciences-stock-skyrocketing-on-monday

Revelation Biosciences reveals positive safety and biomarker data from its Phase 1 study (RVL-HV02) of Gemini. The study met it...

 revelation-biosciences-announces-phase-1-results-for-gemini-demonstrates-safety-tolerability-and-dose-dependent-biomarker-changes-enables-further-development-across-multiple-indications

-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity--Gemini was safe...

 revelation-biosciences-q1-eps-246-misses-177-estimate

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.46) per share which missed the analyst consensus estimate...

 revelation-biosciences-q4-eps-833-beats-1377-estimate

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(8.33) per share which beat the analyst consensus estimate o...

 revelation-biosciences-presented-data-showing-pretreatment-with-gemini-improved-kidney-function-with-reduced-serum-blood-urea-nitrogen-and-creatinine-urine-c-reactive-protein-and-acute-kidney-injury-related-inflammation

Gemini is the company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) for systemic administration....

 revelation-biosciences-commences-first-in-human-phase-1-clinical-study-of-gemini

 -Top-line data including safety, tolerability, and biomarker activity anticipated this summer--This Phase 1 clinical study dat...

 top-5-health-care-stocks-that-are-preparing-to-pump-in-february

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 why-skechers-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarte...

 why-meta-shares-are-trading-higher-by-over-16-here-are-20-stocks-moving-premarket

Shares of Meta Platforms, Inc. (NASDAQ: META) rose sharply in today’s pre-market trading as the company reported upbeat fourth-...

 dow-jumps-250-points-honeywell-issues-weak-forecast

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION